Kestra Medical Technologies (NASDAQ:KMTS) Receives “Buy” Rating from BTIG Research

Posted by Brian Himes on Sep 2nd, 2026

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at BTIG Research in a research note issued on Wednesday, Benzinga reports. They presently have a $32.00 target price on the stock. BTIG Research’s price target suggests a potential upside of 27.39% from the company’s previous close.

Several other brokerages have also recently weighed in on KMTS. Oppenheimer assumed coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating on the stock. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. Weiss Ratings downgraded shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. Wall Street Zen upgraded shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Kestra Medical Technologies in a research report on Monday, August 10th. They set an “overweight” rating and a $30.00 price target for the company. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $28.14.

Read Our Latest Research Report on KMTS

Kestra Medical Technologies Price Performance

KMTS stock opened at $25.12 on Wednesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41. Kestra Medical Technologies has a 1 year low of $15.42 and a 1 year high of $30.00. The firm has a 50-day moving average of $25.42 and a 200 day moving average of $22.79. The company has a market cap of $1.47 billion, a P/E ratio of -10.38 and a beta of 0.62.

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last posted its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million for the quarter. On average, sell-side analysts forecast that Kestra Medical Technologies will post -2.29 EPS for the current year.

Insider Activity at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 51,900 shares of Kestra Medical Technologies stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $24.52, for a total transaction of $1,272,588.00. Following the completion of the transaction, the insider owned 475,215 shares in the company, valued at approximately $11,652,271.80. The trade was a 9.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Traci S. Umberger sold 8,752 shares of the business’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $22.60, for a total value of $197,795.20. Following the completion of the sale, the insider directly owned 206,995 shares in the company, valued at $4,678,087. This trade represents a 4.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 238,164 shares of company stock worth $5,700,952 over the last quarter. 5.30% of the stock is currently owned by company insiders.

Institutional Trading of Kestra Medical Technologies

Several institutional investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its holdings in Kestra Medical Technologies by 137.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock worth $115,878,000 after buying an additional 2,529,851 shares during the last quarter. Brown Advisory Inc. grew its holdings in shares of Kestra Medical Technologies by 34.1% during the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after buying an additional 428,996 shares during the last quarter. Alliancebernstein L.P. increased its position in shares of Kestra Medical Technologies by 13.7% during the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock valued at $35,449,000 after acquiring an additional 179,885 shares in the last quarter. Eventide Asset Management LLC increased its position in shares of Kestra Medical Technologies by 5.4% during the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after acquiring an additional 65,288 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in Kestra Medical Technologies by 180.8% in the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock worth $25,221,000 after acquiring an additional 612,343 shares during the last quarter.

Kestra Medical Technologies Company Profile

(Get Free Report)

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.